How to reconstitute LL-37: mixing and storage

A human defense peptide with mixed topical wound-trial results and no established injection regimen.

Also called: LL37, Cathelicidin LL-37, hCAP18/LL-37.

Anti-inflammatory and antimicrobial peptides · Human cathelicidin antimicrobial and immune-signaling peptide.

Comes as: Trial topical gel or cream, Community lyophilised powder vials, Engineered bacterial capsules in COVID studies.

Mixed with: Community posts describe bacteriostatic water. HEAL used a sterile PVA diluent for topical application, not bacteriostatic injection water..

Common vial sizes: 5 mg. Common water amounts: 4 mL.

  • An independent discussion describes a 5 mg vial with 4 mL bacteriostatic water. This does not establish stability or sterility.
  • Topical trial concentrates were mixed with 13.1% PVA to make 0.5 or 1.6 mg/mL LL-37 in 10.5% PVA.
  • No evidence supports a universal 28-day expiry after mixing. Sterility and chemical stability are separate questions.

Before mixing: No approved vial-storage label or validated expiry for community products was found.

After mixing: No validated shelf life for community mixtures. The wound trial mixed its controlled formulation immediately before application.

Related to LL-37

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.